Posted by Michael Wonder on 29 Apr 2024
Celltrion USA signs agreement with Express Scripts for its therapy for autoimmune diseases including the first FDA approved subcutaneous infliximab Zymfentra
28 April 2024 - Celltrion USA announced today that it has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers negotiating on behalf of health plans covering more than 100 million people.
The agreement, effective 4 April 2024 provides Zymfentra Preferred Brand Access on the Express Scripts National Preferred Formulary serving 21.9 million insured lives. Express Scripts provides plan participants such as Health Plans of the pharmacy benefit managers the ability to add Zymfentra (infliximab-dyyb) to their formularies.
